论文部分内容阅读
近年来,免疫单药治疗肺癌的疗效显著。许多基础研究和临床研究的结果均表明,免疫治疗联合化疗可能取得较单一疗法更加优异的疗效。化疗可能直接刺激先天性免疫反应和获得性免疫细胞,阻断促进肿瘤进展的免疫抑制通路,提高肿瘤细胞的抗原性或免疫原性,或者加强免疫效应机制的敏感性。目前,免疫治疗联合化疗的临床研究正在进行之中,但不良反应亦不容忽视,如何确定更佳组合方案,仍需进一步的研究。
In recent years, immunotherapy monotherapy lung cancer significant effect. Many basic research and clinical studies have shown that immunotherapy combined with chemotherapy may achieve more excellent than monotherapy. Chemotherapy may directly stimulate innate and acquired immune cells, block immunosuppressive pathways that promote tumor progression, increase the antigenicity or immunogenicity of tumor cells, or enhance the sensitivity of immune effector mechanisms. At present, the clinical research of immunotherapy combined with chemotherapy is underway, but adverse reactions should not be neglected. How to determine a better combination regimen still needs further study.